Aravive (NASDAQ:ARAV) Lowered to Hold at Zacks Investment Research

Zacks Investment Research downgraded shares of Aravive (NASDAQ:ARAV) from a buy rating to a hold rating in a report released on Wednesday morning, Zacks.com reports.

According to Zacks, “Aravive Inc. is a biotechnology company. It develops therapeutic proteins for the treatment of metabolic diseases and endocrine disorders. Aravive Inc. is based in TX, United States. “

A number of other equities research analysts have also weighed in on the stock. ValuEngine lowered shares of Zumiez from a hold rating to a sell rating in a report on Tuesday, July 2nd. Piper Jaffray Companies raised their price objective on shares of Boot Barn from $33.00 to $41.00 and gave the company an overweight rating in a report on Monday, May 13th. Finally, Wedbush set a $269.00 target price on shares of United Therapeutics and gave the company a buy rating in a research report on Monday, April 8th.

Shares of ARAV traded down $0.11 during midday trading on Wednesday, reaching $6.00. The stock had a trading volume of 2,900 shares, compared to its average volume of 21,476. Aravive has a 1-year low of $3.07 and a 1-year high of $12.90. The business has a fifty day moving average price of $5.93. The firm has a market capitalization of $66.52 million, a P/E ratio of -0.56 and a beta of 2.30. The company has a debt-to-equity ratio of 0.17, a quick ratio of 7.78 and a current ratio of 7.78.

Aravive (NASDAQ:ARAV) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.42) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.86) by $0.44. The firm had revenue of $1.70 million during the quarter. Research analysts expect that Aravive will post -2.19 earnings per share for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in shares of Aravive in the 4th quarter valued at $621,000. Dimensional Fund Advisors LP purchased a new position in shares of Aravive in the 4th quarter valued at $484,000. Two Sigma Investments LP purchased a new position in shares of Aravive in the 4th quarter valued at $124,000. Geode Capital Management LLC purchased a new position in shares of Aravive in the 4th quarter valued at $105,000. Finally, Two Sigma Advisers LP purchased a new position in shares of Aravive in the 4th quarter valued at $87,000. 27.57% of the stock is currently owned by hedge funds and other institutional investors.

About Aravive

Aravive, Inc, a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer.

Featured Article: Systematic Risk

Get a free copy of the Zacks research report on Aravive (ARAV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with MarketBeat.com's FREE daily email newsletter.